Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on September 12, 2017, reporting events occurring on September 7, 2017. The company is an emerging growth company incorporated in Delaware. The filing details amendments to existing debt instruments to facilitate a potential future equity financing.
Key Financial Metrics
- Debt Outstanding: As of September 11, 2017, the aggregate outstanding principal and accrued interest on the "2017 Notes" totaled $1,254,301.
- Recent Financing: Since March 1, 2017, the company raised $1,230,000 in aggregate proceeds via convertible promissory notes.
- Warrants: The 2017 Notes included seven-year warrants to purchase 492,000 shares at an exercise price of $5.90 per share.
- Liquidity and Margins: The filing text does not provide clear values for revenue, profit, cash flow, or operating margins.
Material Changes and Agreements
On September 7, 2017, the company entered into Letter Agreements with holders of the 2017 Notes to modify conversion terms in the event of a "Qualified Financing" (a firm commitment underwritten offering resulting in at least $2,000,000 in proceeds and listing on a major exchange) consummated prior to December 31, 2017.
- Conversion Price: Notes will convert at the lesser of 80% of the Qualified Financing price per share or $5.90 per share.
- Lock-Up: Note holders agreed to a 180-day lock-up agreement commencing on the date of the final prospectus for the Qualified Financing.
- Ownership Cap: If conversion would cause a holder to own more than 9.99% of common stock, they may elect to receive Series C Convertible Preferred Stock instead.
Outlook, Risks, and Contingencies
The primary contingency described is the company's ability to complete a Qualified Financing by December 31, 2017. The modified terms are designed to incentivize this event by offering a discounted conversion price (80% of the offering price) to existing note holders. The filing does not provide specific management commentary on future revenue guidance or operational risks beyond the financing structure.
Investor Verification Checklist
- Verify the company name is NanoVibronix, Inc., as the input metadata incorrectly referenced Envue Medical, Inc.
- Confirm the status of the Qualified Financing deadline (December 31, 2017) and whether it was met.
- Review the full text of the Letter Agreement (Exhibit 10.1) for specific covenants and default provisions.
- Assess the dilution impact of the 80% conversion discount and the 492,000 existing warrants.
- Check subsequent filings for the actual listing status on NYSE American or Nasdaq markets.